MAP2K7 and metastatic melanoma: Targeted therapeutics that suppress melanoma growth such as BRAF inhibitors Vemurafenib or Dabrafenib, or the direct MEK inhibitors Cobimetinib or Tranetinib,36 have revolutionized metastatic melanoma therapy and have at last improved patient survival.